BIOTYPE Introduces Diagnostics and Cancer Profiling Assays at MEDICA 2026
Posted on 16 Nov 2026
BIOTYPE (Dresden, Germany) presents its molecular diagnostic assays and testing technologies at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. The company highlights new solutions for molecular oncology, pharmacogenetics, and automated sample preparation, alongside its broader portfolio of in vitro diagnostic (IVD) assays and development services for clinical laboratories and diagnostic manufacturers.
Among the products on display is the new Mentype AMLplus Mutation Analysis Kit, a multiplex PCR assay for detecting genetic mutations associated with acute myeloid leukemia (AML). The assay simultaneously analyzes mutation hotspots in IDH1, IDH2, FLT3, NPM1, and CEBPA using blood or bone marrow samples. It provides results in approximately four hours after nucleic acid extraction and includes software for standardized data interpretation.
BIOTYPE also presents the new ExaccType ESR1 dPCR Kit, designed to detect 11 ESR1 mutations across exons 5, 7, and 8 using digital PCR. The research-use-only assay demonstrated detection at mutant allele frequencies as low as 0.1% under evaluated conditions. It supports the analysis of DNA, including plasma-derived cell-free DNA, for research into breast cancer progression, endocrine resistance, and liquid biopsy biomarkers.
Another addition is the ExaccType DPYD Kit, a multiplex quantitative PCR (qPCR) assay for detecting seven predefined DPYD variants associated with fluoropyrimidine metabolism. The research-use-only test analyzes purified genomic DNA or whole blood and uses four multiplex reactions per sample. It is designed to support pharmacogenetic research and investigations into genetic factors affecting drug metabolism.
The exhibition also features BIOTYPE's portfolio of molecular diagnostic assays supporting hemato-oncology, chimerism monitoring, solid tumor profiling, and liquid biopsy applications. The company presents its IVDR-compliant testing solutions alongside research assays, highlighting approaches to identifying molecular alterations relevant to cancer diagnosis, disease monitoring, and precision medicine.
In addition to molecular assays, BIOTYPE showcases automated sample preparation technologies designed to streamline laboratory workflows. These solutions support sample processing and preparation for downstream molecular analysis, with applications in oncology and other diagnostic fields. Automation is intended to improve workflow standardization and reduce manual handling during laboratory testing.
BIOTYPE also highlights its contract development and manufacturing services for molecular diagnostics. The company provides assay development, optimization, and manufacturing support to diagnostic and biotechnology companies, covering different stages of product development. These services complement its existing molecular testing portfolio and support the development of new diagnostic technologies.
BIOTYPE exhibits at Booth 3C72-2 in Hall 3, where visitors can explore its molecular diagnostic technologies and discuss potential research and commercial collaborations. The company is using its participation at MEDICA 2026 to connect with laboratory professionals, distributors, and diagnostic manufacturers as it expands its molecular diagnostics activities.